Literature DB >> 1355269

Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures.

M Nilsson1, E Hansson, L Rönnbäck.   

Abstract

Astrocytes have been proposed to regulate the extracellular space in the brain, even if rather little is known about their specific functions. One possibility for obtaining more knowledge on the functions of astroglial cells is to examine how they respond on exposure to pharmacological agents. Na(+)-valproate is an anticonvulsive drug which is used in the treatment of several types of epilepsy. The mechanisms of action of the drug are not fully understood, but the GABA-ergic system, both in neurons and astrocytes, has been shown to be affected. In the present study, the effects of valproate were investigated on astroglial cells in primary cultures from newborn rat cerebral cortex. The transport of the drug itself and its effects on the transport of the amino acid transmitters glutamate, aspartate and gamma-aminobutyric acid (GABA) into astrocytes were examined. The [3H]valproate transport into the astrocytes was increased after exposure to L-glutamate but not L-aspartate. On the other hand, after acute exposure for the drug, the transport of [3H]L-glutamate and [3H]L-aspartate decreased, as also did the affinity but not the transport capacity for the [3H]GABA uptake. However, after 5 days chronic valproate exposure, no effects could be seen on the uptake kinetics of L-glutamate or L-aspartate. For GABA, the affinity decreased, while the transport capacity remained unchanged compared with controls. The results showed that valproate, glutamate, aspartate and GABA were capable of interacting significantly with each others transport into the astrocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355269     DOI: 10.1007/bf00974573

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

1.  Receptor regulation of the glutamate, GABA and taurine high-affinity uptake into astrocytes in primary culture.

Authors:  E Hansson; L Rönnbäck
Journal:  Brain Res       Date:  1991-05-10       Impact factor: 3.252

Review 2.  Neurophysiological and biochemical changes evoked by valproic acid in the central nervous system.

Authors:  D Cotariu; J L Zaidman; S Evans
Journal:  Prog Neurobiol       Date:  1990       Impact factor: 11.685

3.  Ultrastructural features of a brain injury model in cat. I. Vascular and neuroglial changes and the prevention of astroglial swelling by a fluorenyl (aryloxy) alkanoic acid derivative (L-644,711).

Authors:  K D Barron; M P Dentinger; H K Kimelberg; L R Nelson; R S Bourke; S Keegan; R Mankes; E J Cragoe
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

4.  Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA.

Authors:  W Löscher
Journal:  J Neurochem       Date:  1980-06       Impact factor: 5.372

5.  GABAA responses in hippocampal neurons are potentiated by glutamate.

Authors:  A Stelzer; R K Wong
Journal:  Nature       Date:  1989-01-12       Impact factor: 49.962

6.  Sodium valproate stimulates the particulate form of glutamine synthetase in rat brain.

Authors:  P Phelan; C Regan; C Kilty; A Dunne
Journal:  Neuropharmacology       Date:  1985-09       Impact factor: 5.250

7.  Amino acid and monoamine transport in primary astroglial cultures from defined brain regions.

Authors:  E Hansson; P Eriksson; M Nilsson
Journal:  Neurochem Res       Date:  1985-10       Impact factor: 3.996

8.  Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids.

Authors:  B J Perlman; D B Goldstein
Journal:  Mol Pharmacol       Date:  1984-07       Impact factor: 4.436

9.  Characterization of uptake and release processes for D- and L-aspartate in primary cultures of astrocytes and cerebellar granule cells.

Authors:  J Drejer; O M Larsson; A Schousboe
Journal:  Neurochem Res       Date:  1983-02       Impact factor: 3.996

10.  Studies on gamma-aminobutyric acid transport in cobalt experimental epilepsy in the rat.

Authors:  S M Ross; C R Craig
Journal:  J Neurochem       Date:  1981-03       Impact factor: 5.372

View more
  7 in total

Review 1.  [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].

Authors:  K Kollewe; R Dengler; S Petri
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

2.  Glutamatergic effects of divalproex in adolescents with mania: a proton magnetic resonance spectroscopy study.

Authors:  Jeffrey R Strawn; Nick C Patel; Wen-Jang Chu; Jing-Huei Lee; Caleb M Adler; Mi Jung Kim; Holly S Bryan; David C Alfieri; Jeffrey A Welge; Thomas J Blom; Jayasree J Nandagopal; Stephen M Strakowski; Melissa P DelBello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-05-05       Impact factor: 8.829

3.  Uptake of GABA and activity of GABA transaminase in blood platelets from children with absence epilepsy.

Authors:  Sirpa Rainesalo; Kai Eriksson; Pirjo Saransaari; Tapani Keränen
Journal:  Neurochem Res       Date:  2004-10       Impact factor: 3.996

4.  The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates.

Authors:  J F Dixon; L E Hokin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

Review 5.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Valproate disturbs the balance between branched and aromatic amino acids in rats.

Authors:  Piotr Maciejak; Janusz Szyndler; Karolina Kołosowska; Danuta Turzyńska; Alicja Sobolewska; Jerzy Walkowiak; Adam Płaźnik
Journal:  Neurotox Res       Date:  2013-11-19       Impact factor: 3.911

7.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.